148 related articles for article (PubMed ID: 31777116)
1. TET2 promotor methylation and TET2 protein expression in pediatric posterior fossa ependymoma.
Pierscianek D; Teuber-Hanselmann S; Ahmadipour Y; Darkwah Oppong M; Unteroberdörster M; Müller O; Jabbarli R; Sure U; Zhu Y; El Hindy N
Neuropathology; 2020 Apr; 40(2):138-143. PubMed ID: 31777116
[TBL] [Abstract][Full Text] [Related]
2. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity within the PF-EPN-B ependymoma subgroup.
Cavalli FMG; Hübner JM; Sharma T; Luu B; Sill M; Zapotocky M; Mack SC; Witt H; Lin T; Shih DJH; Ho B; Santi M; Emery L; Hukin J; Dunham C; McLendon RE; Lipp ES; Gururangan S; Grossbach A; French P; Kros JM; van Veelen MC; Rao AAN; Giannini C; Leary S; Jung S; Faria CC; Mora J; Schüller U; Alonso MM; Chan JA; Klekner A; Chambless LB; Hwang EI; Massimino M; Eberhart CG; Karajannis MA; Lu B; Liau LM; Zollo M; Ferrucci V; Carlotti C; Tirapelli DPC; Tabori U; Bouffet E; Ryzhova M; Ellison DW; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Pfister SM; Taylor MD; Aldape K; Pajtler KW; Kool M; Ramaswamy V
Acta Neuropathol; 2018 Aug; 136(2):227-237. PubMed ID: 30019219
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and microRNA profile analysis for CD44 positive expression pediatric posterior fossa ependymoma.
Shu C; Wang Q; Yan X; Wang J
Clin Transl Oncol; 2018 Nov; 20(11):1439-1447. PubMed ID: 29704232
[TBL] [Abstract][Full Text] [Related]
5. Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome.
Sasaki A; Hirato J; Hirose T; Fukuoka K; Kanemura Y; Hashimoto N; Kodama Y; Ichimura K; Sakamoto H; Nishikawa R
Brain Tumor Pathol; 2019 Apr; 36(2):92-101. PubMed ID: 30929114
[TBL] [Abstract][Full Text] [Related]
6. Utility of copy number variants in the classification of intracranial ependymoma.
Evenson M; Cai C; Hucthagowder V; McNulty S; Neidich J; Kulkarni S; Dahiya S
Cancer Genet; 2020 Jan; 240():66-72. PubMed ID: 31794935
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.
Thomas C; Thierfelder F; Träger M; Soschinski P; Müther M; Edelmann D; Förster A; Geiler C; Kim HY; Filipski K; Harter PN; Schittenhelm J; Eckert F; Ntoulias G; May SA; Stummer W; Onken J; Vajkoczy P; Schüller U; Heppner FL; Capper D; Koch A; Kaul D; Paulus W; Hasselblatt M; Schweizer L
Acta Neuropathol; 2021 Jun; 141(6):959-970. PubMed ID: 33755803
[TBL] [Abstract][Full Text] [Related]
8. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.
Gojo J; Lötsch D; Spiegl-Kreinecker S; Pajtler KW; Neumayer K; Korbel P; Araki A; Brandstetter A; Mohr T; Hovestadt V; Chavez L; Kirchhofer D; Ricken G; Stefanits H; Korshunov A; Pfister SM; Dieckmann K; Azizi AA; Czech T; Filipits M; Kool M; Peyrl A; Slavc I; Berger W; Haberler C
Neuro Oncol; 2017 Sep; 19(9):1183-1194. PubMed ID: 28371821
[TBL] [Abstract][Full Text] [Related]
9. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.
Pajtler KW; Wen J; Sill M; Lin T; Orisme W; Tang B; Hübner JM; Ramaswamy V; Jia S; Dalton JD; Haupfear K; Rogers HA; Punchihewa C; Lee R; Easton J; Wu G; Ritzmann TA; Chapman R; Chavez L; Boop FA; Klimo P; Sabin ND; Ogg R; Mack SC; Freibaum BD; Kim HJ; Witt H; Jones DTW; Vo B; Gajjar A; Pounds S; Onar-Thomas A; Roussel MF; Zhang J; Taylor JP; Merchant TE; Grundy R; Tatevossian RG; Taylor MD; Pfister SM; Korshunov A; Kool M; Ellison DW
Acta Neuropathol; 2018 Aug; 136(2):211-226. PubMed ID: 29909548
[TBL] [Abstract][Full Text] [Related]
10. Radiology Profile as a Potential Instrument to Differentiate Between Posterior Fossa Ependymoma (PF-EPN) Group A and B.
Yonezawa U; Karlowee V; Amatya VJ; Takayasu T; Takano M; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
World Neurosurg; 2020 Aug; 140():e320-e327. PubMed ID: 32428725
[TBL] [Abstract][Full Text] [Related]
11. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
[TBL] [Abstract][Full Text] [Related]
12. Characterization of global 5-hydroxymethylcytosine in pediatric posterior fossa ependymoma.
Wu T; Zhang ZW; Li S; Wang B; Yang Z; Li P; Zhang J; Tong WM; Li C; Zhao F; Niu Y; Liu P
Clin Epigenetics; 2020 Jan; 12(1):19. PubMed ID: 31992357
[TBL] [Abstract][Full Text] [Related]
13. Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma.
Hoffman LM; Donson AM; Nakachi I; Griesinger AM; Birks DK; Amani V; Hemenway MS; Liu AK; Wang M; Hankinson TC; Handler MH; Foreman NK
Acta Neuropathol; 2014 May; 127(5):731-45. PubMed ID: 24240813
[TBL] [Abstract][Full Text] [Related]
14. TET2 Promoter DNA Methylation and Expression in Childhood Acute Lymphoblastic Leukemia.
Bahari G; Hashemi M; Naderi M; Taheri M
Asian Pac J Cancer Prev; 2016; 17(8):3959-62. PubMed ID: 27644645
[TBL] [Abstract][Full Text] [Related]
15. Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.
Kamdar S; Isserlin R; Van der Kwast T; Zlotta AR; Bader GD; Fleshner NE; Bapat B
Clin Epigenetics; 2019 Mar; 11(1):54. PubMed ID: 30917865
[TBL] [Abstract][Full Text] [Related]
16. Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas.
Puget S; Grill J; Valent A; Bieche I; Dantas-Barbosa C; Kauffmann A; Dessen P; Lacroix L; Geoerger B; Job B; Dirven C; Varlet P; Peyre M; Dirks PB; Sainte-Rose C; Vassal G
J Clin Oncol; 2009 Apr; 27(11):1884-92. PubMed ID: 19289631
[TBL] [Abstract][Full Text] [Related]
17. Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features - a retrospective analysis of the HIT ependymoma trial cohort.
Jünger ST; Mynarek M; Wohlers I; Dörner E; Mühlen AZ; Velez-Char N; von Hoff K; Rutkowski S; Warmuth-Metz M; Kortmann RD; Timmermann B; Rahmann S; Klein-Hitpass L; von Bueren AO; Pietsch T
Acta Neuropathol Commun; 2019 Nov; 7(1):181. PubMed ID: 31727173
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review.
Nobusawa S; Hirato J; Yokoo H
Brain Tumor Pathol; 2014 Oct; 31(4):229-33. PubMed ID: 25182241
[TBL] [Abstract][Full Text] [Related]
19. MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL.
Poole CJ; Lodh A; Choi JH; van Riggelen J
Epigenetics Chromatin; 2019 Jul; 12(1):41. PubMed ID: 31266538
[TBL] [Abstract][Full Text] [Related]
20. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.
Iancu IV; Botezatu A; Plesa A; Huica I; Fudulu A; Albulescu A; Bostan M; Mihaila M; Grancea C; Manda DA; Dobrescu R; Vladoiu SV; Anton G; Badiu CV
Cancer Biomark; 2020; 28(2):255-268. PubMed ID: 32390600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]